NCT07437105RecruitingPhase 1
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272 in combination with deutivacaftor (D-IVA) with or without tezacaftor (TEZ) in healthy subjects.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- First submitted
- 20 Feb 2026
- Start date
- 25 Feb 2026
- Primary completion date
- 26 Jun 2027
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Diseases
- Cystic fibrosis
- NCT number
- NCT07437105
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 160
- From 25 Feb 2026 to the primary completion date, 26 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
Other illness
- Any condition possibly affecting drug absorption
- Other protocol defined Inclusion/Exclusion criteria may apply.
Who the study is looking for
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
- A total body weight of more than (\>) 50 kg
- Male and Female participants of non-childbearing potential
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Celerion - Tempe Coordinator of this site? Confirm its status | Tempe | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.